Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

Patient-Level Data for Drugs and Biological Products Submissions Containing Real-World Data and Real-World Evidence; Request for Information

By Human Services Department, Food, Health, Drug Administration · Nov 11, 2026, 11:00 PM CST

Read full article at Federal Register
The Food and Drug Administration (FDA or Agency), is announcing a request for information (RFI) from interested parties to share perspectives on patient-level data access related to the use of real-world evidence (RWE) in regulatory decision-making for drugs and biological product submissions. The purpose of this RFI is to solicit input from interested parties on innovative solutions to address th

Excerpt shown under fair-use limits. Full text remains with the original publisher.

People in this coverage

Explore their history and attributable record. Being mentioned does not imply endorsement.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

FramingThe announcement frames the RFI as a collaborative effort to solve challenges, positioning the FDA as seeking external expertise.

Audience TargetingThe list explicitly names a broad set of stakeholders, indicating an inclusive outreach strategy.

Context

AI analysis

Missing context

The announcement does not explain the specific regulatory challenges that have prompted the RFI, nor does it detail how the FDA intends to use the information gathered, any timelines for response, or potential impacts on existing submission processes.

Important context

Real‑world evidence is increasingly used by regulators to complement clinical trial data, and patient‑level data raises privacy, data‑standardization, and feasibility concerns that the FDA is seeking to address through stakeholder input.

Opinion vs. reporting

AI analysis

The text is purely informational; it reports the FDA's RFI without editorializing or presenting opinion.